Clinical Neuroscience - 2010;63(05-06)

Clinical Neuroscience

MAY 30, 2010

[Neurology! Adieau? (Part 1)]

SZIRMAI Imre

[The neurological practice suffered considerable changes during the last twenty years. The recent therapeutic methods and the acceptance of the ideology of evidence based medicine, which is based on confidence in statistics, changed the reasoning of the neurologists. Therapy protocols intrude into the field of individual medicine, and doctors accept treatment schemes to alleviate responsibility of their decisions. In contrast with this, recent achievements in pharmacogenetics emphasize the... tovább »

Clinical Neuroscience

MAY 30, 2010

[Neurology! Adieau? (Part 2)]

SZIRMAI Imre

[Teaching of neurologists is indisposed worldwide. University tutors are engaged in teaching, research and patient-care. This triple challenge is very demanding, and results in permanent insecurity of University employees. To compensate for the insufficient clinical training, some institutes in the USA employ academic staff members exclusively for teaching. The formation of new subspecialties hinders the education and training of general neurologists. At the present four generations of medical... tovább »

Clinical Neuroscience

MAY 30, 2010

[Image fusion guided brachytherapy of brain tumors]

JULOW Jenő

[The paper is the summary of mostly published works of the clinical results of intracavitary Yttrium-90 colloid irradiation of recurrent cystic craniopharyngiomas, and Iodine-125 interstitial irradiation of gliomas, pinealomas, brainstem tumors, recurrent meningeomas, solid craniopharyngiomas and metastases. It concisely demonstrates the usefulness of image fusion in the verification of isotope seeds and catheters, the comparison of 125 Iodine stereotactic brachytherapy and LINAC radiosurgery... tovább »

Clinical Neuroscience

MAY 30, 2010

[Clinical studies on pramipexol retard]

KLIVÉNYI Péter, VÉCSEI László

[Pramipexol retard is the newest drug for the treatment of Parkinson’s disease. The prolonged release of the agent in this preparation allows a more continuous dopaminergic stimulation than previous preparations, without reducing the agent’s already known and proven clinical efficiency. In addition, it has a more favourable adverse effect profile than previous preparations, and patient compliance can also be better as it needs to be taken only once daily. These benefits have been proven in... tovább »

Clinical Neuroscience

MAY 30, 2010

[Epidemiology of dementia in Hungary]

ÉRSEK Katalin, KÁRPÁTI Krisztián, KOVÁCS Tibor, CSILLIK Gabriella, GULÁCSI L. Ádám, GULÁCSI László

[Objective - To estimate the epidemiology and the distribution of disease severity of dementia in Hungary, using published data. To estimate the demented population of 2008 and to make a projection for 2050. Methodology - With an outlook for the international professional literature and the available Hungarian information we examine the epidemiology of dementia in Hungary by age-groups and disease severity (according to MMSE categories), then make our estimation for the entire population. ... tovább »

Clinical Neuroscience

MAY 30, 2010

[Antinociceptive effect of vinpocetine - a comprehensive survey]

CSILLIK Bertalan, MIHÁLY András, KNYIHÁR-CSILLIK Elizabeth

[Blockade of retrograde transport of nerve growth factor (NGF) in a peripheral sensory nerve is known to induce transganglionic degenerative atrophy (TDA) of central sensory terminals in the upper dorsal horn of the related, ipsilateral segments(s) of the spinal cord. The ensuing temporary blockade of transmission of nociceptive impulses has been utilized in the therapy of intractable pain, using transcutaneous iontophoresis of the microtubule inhibitors vincristin and vinblastin, drugs which... tovább »

Clinical Neuroscience

MAY 30, 2010

[Intracranial propagation of invasive aspergilloma in an immuncompromised patient]

SIMON Márta, VASTAGH Ildikó, VÁRALLYAY György, TURÁNYI Eszter, SRÉTER Lídia, CZIRJÁK Sándor, BERECZKI Dániel

[Aspergillus infection of the central nervous system is a rare disease, occasionally seen among immunocompromised patients. The most frequent pathway is hematogenic dissemination. Less known is the direct propagation from the paranasal sinuses, which is usually observed in immunocompetent patients. We report a patient who developed cavernous sinus syndrome due to an invasive intracranial aspergilloma after longlasting chemo- and steroid therapy for chronic lymphoid leukemia and immunhemolytic... tovább »

Clinical Neuroscience

MAY 30, 2010

Clinical Neuroscience

MAY 30, 2010

[ABSTRACTS OF THE 5TH PANNONIAN SYMPOSIUM ON CNS INJURYPécs, 13-15, May, 2010]

[Abstracts of the 5th pannonian symposium on cns injury pecs 13 15 may 2010 2010;63(05-06)]